2025 英卡思亚洲年会
大会日程

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: I'd like to share the principles and usage of Curejet, which is currently used as the main treatment for acne atrophic scar treatment.

Introduction: Curejet is a needless free injector and is FDA-approved in Korea in 2022 and is used in various dermatological areas such as scar, striae distensae, rejuvenation and hair loss.

Materials / method: Curejet can be used in a variety of ways depending on the shape of the scar.

Results: It is usually recommended five times per every three months, and although the improvement effect varies depending on the shape of the scar, it generally shows satisfactory results without side effects.

Conclusion: Curejet is currently in an irreplaceable position when it comes to scar treatment.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: Bazbiomedic

您是否接受过关于这项研究的任何酬金或其他报酬？
是
请注明名称（个人，公司，学会等等）: Bazbiomedic

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： Bazbiomedic

Objectives: Our research aims to introduce a new triple precursor technology (Pro-GHL) designed to deliver superior tone and skin barrier benefit through de novo biosynthesis in the skin.

Introduction: The epidermis acts as the body’s primary defense, relying on components like lipids, hyaluronic acid (HA), and Glutathione (GSH) for barrier function, hydration, and resistance to oxidative stress. However, limitations in topical applications of these biomolecules call for novel approaches.

Materials / method: In vitro and ex vivo studies were conducted to evaluate the efficacy of Pro-GHL in protecting against barrier disruption and hyperpigmentation. Three pigmented 3D skin models were employed, and skin explant under UV exposure was adopted. In a single-center, open label application study, we assessed the efficacy of the day serum system in 44 healthy female participants aged 25–45 years with spots over a 12-week treatment period. Clinical expert evaluation and instrument measurements were conducted at baseline, week 4, week 8 and week 12 post treatment.

Results: Pro-GHL demonstrated promising restoration and protection effects against barrier disruption and hyperpigmentation. The formulation containing Pro-GHL with SPF 50 showed improved superior performance over the one without UV filter. After 12 weeks of topical application, a significant improvement in skin evenness, hydration and reduction in spots was observed in week 12 compared with baseline.

Conclusion: In conclusion, the study introduces an innovative biostimulator skin care approach designed to target hyperpigmentation by combining a synergistic blend of three precursors for a comprehensive solution. The consistent results from in vitro, ex vivo and in vivo reinforce Pro-GHL’s potential as a novel, effective and comprehensive skincare approach to fortify skin’s defense system from within and prevent accumulation of tissue damages in response to extrinsic stressors.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。